Opdivo

BMS unveils long-term results for Opdivo in kidney cancer

Results include updated data for Opdivo with or without Yervoy. Bristol-Myers Squibb has unveiled long-term results for Opdivo in renal cell carcinoma, which demonstrated efficacy with and without CTLA4 ... BMS also reported updated results from its

20 for 2020 – Five pharma companies to watch

The merger was completed shortly after BMS reported the first decline in quarterly sales of its immuno-oncology blockbuster Opdivo (nivolumab) since its launch five years ago, and 2020 is viewed ... Opdivo is being squeezed out of the market by Merck &Co/

Revenue growth at Ipsen numbs pain of palovarotene calamity

The company is waiting for phase 3 results for Cabometyx in combination with Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in first-line renal cell carcinoma, which could add further momentum

NICE turns down Keytruda/Inlyta combo for kidney cancer

The results outperformed MSD’s main rival in the checkpoint inhibitor category – Bristol-Myers Squibb – which had built a useful position in first-line RCC with its combination of Opdivo (nivolumab) ... Opdivo/Yervoy reduced the risk of death by 37%

Exelixis bounces back with new prostate cancer data

Exelixis is also testing cabozantinib in a host of other clinical trials, including a phase 3 trial in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) in previously untreated advanced or

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]